


Claims

1. A compound of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

- 5 A is N or CH;
 R¹ is H, F, Cl, CN, C₁-C₂ alkyl, C₁-C₂ fluoroalkyl or C₁-C₂ alkoxy, where each said C₁-C₂ alkyl and C₁-C₂ fluoroalkyl is optionally substituted by R²⁰;
 U is NR² or CR³;
 V is N or CR⁴ when U is NR²; and
 10 V is NR⁵ when U is CR³;
 X is CR⁶ or N;
 Y is CR⁷ or N;
 Z is CR⁸ or N;
 R² and R³ are H, C₁-C₅ alkyl, C₁-C₅ fluoroalkyl, C₃-C₈ cycloalkyl or 3-6 membered
 15 heterocyclyl, where each said C₁-C₅ alkyl and C₁-C₅ fluoroalkyl is optionally substituted by R²⁰ and each said C₃-C₈ cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R²¹;
 R⁴ is H, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy, C₁-C₄ fluoroalkoxy, C(O)R^a, C(O)NR^b, C₃-C₈ cycloalkyl or 3-6 membered heterocyclyl, where each said C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy and C₁-C₄ fluoroalkoxy is optionally substituted by R²⁰, each said C₃-C₈ cycloalkyl
 20 and 3-6 membered heterocyclyl is optionally substituted by R²¹, R^a is C₁-C₂ alkyl, and each R^b is independently H or C₁-C₂ alkyl; and
 R⁵ is H, C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R²⁰; or
 R² can be taken together with R⁴, or R³ can be taken together with R⁵, to form a 5-7
 25 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR²⁴, O and S(O)_m as a ring member, which ring is optionally substituted by R²¹;
 R⁶ is H, F, Cl, CN, CH₃, CH₂F, CHF₂ or CF₃;

- R^7 and R^8 are independently H, F, Cl, CN, C₁-C₂ alkyl, C₁-C₂ fluoroalkyl, C₁-C₂ alkoxy or C₁-C₂ fluoroalkoxy, where each said C₁-C₂ alkyl, C₁-C₂ fluoroalkyl, C₁-C₂ alkoxy and C₁-C₂ fluoroalkoxy is optionally substituted by R^{20} ;
- R^9 is H, OH, NH₂, NHCH₃ or N(CH₃)₂;
- 5 each R^{10} is independently F, CN, C₁-C₂ alkyl or C₁-C₂ fluoroalkyl, where each said C₁-C₂ alkyl and C₁-C₂ fluoroalkyl is optionally substituted by R^{20} ;
- Q is NR¹¹ or O; or
- Q is CR¹²R¹³, where R^{12} and R^{13} are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR¹¹ or O as a ring member, which
- 10 ring is optionally further substituted by R^{10} ;
- R^{11} is H, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, SO₂R¹⁴, SO₂NR¹⁵R¹⁶, COR¹⁷, COOR¹⁷ or CONR¹⁸R¹⁹, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R^{20} , SO₂R¹⁴, SO₂NR¹⁵R¹⁶, COR¹⁷, COOR¹⁷ or CONR¹⁸R¹⁹;
- R^{14} is C₁-C₄ alkyl or C₁-C₄ fluoroalkyl;
- 15 each R^{15} and R^{16} is independently H or CH₃;
- R^{17} is C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₃-C₈ cycloalkyl or 3-6 membered heterocyclyl, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R^{20} and each said C₃-C₈ cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R^{21} ;
- each R^{18} and R^{19} is independently H, C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said
- 20 C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R^{20} ;
- each R^{20} is independently OH, C₁-C₂ alkoxy, C₁-C₂ fluoroalkoxy, CN, NR²²R²³, C₃-C₈ cycloalkyl or 3-6 membered heterocyclyl, where each said C₃-C₈ cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R^{21} ;
- each R^{21} is independently F, OH, CN, NR²²R²³, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy
- 25 or C₁-C₄ fluoroalkoxy, where each said C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy and C₁-C₄ fluoroalkoxy is optionally further substituted by OH, NH₂, NHCH₃ or N(CH₃)₂;
- each R^{22} and R^{23} is independently H, C₁-C₃ alkyl, C₁-C₃ fluoroalkyl, C₃-C₈ cycloalkyl or 3-6 membered heterocyclyl, where each said C₁-C₃ alkyl and C₁-C₃ fluoroalkyl is optionally further substituted by OH, C₁-C₂ alkoxy or C₁-C₂ fluoroalkoxy and each said C₃-C₈ cycloalkyl and 3-6
- 30 membered heterocyclyl is optionally further substituted by F, OH, C₁-C₂ alkyl, C₁-C₂ fluoroalkyl, C₁-C₂ alkoxy or C₁-C₂ fluoroalkoxy; or
- R^{22} and R^{23} may be taken together with the nitrogen atom to which they are attached to form an azetidiny ring, where said ring is optionally substituted by F, OH, C₁-C₂ alkyl, C₁-C₂ fluoroalkyl, C₁-C₂ alkoxy or C₁-C₂ fluoroalkoxy;
- 35 R^{24} is H, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, SO₂R²⁵, SO₂NR²⁶R²⁷, COR²⁸, COOR²⁸ or CONR²⁹R³⁰;
- R^{25} is C₁-C₄ alkyl or C₁-C₄ fluoroalkyl;

each R^{26} and R^{27} is independently H or CH_3 ;

R^{28} is C_1 - C_4 alkyl or C_1 - C_4 fluoroalkyl, where each said C_1 - C_4 alkyl and C_1 - C_4 fluoroalkyl is optionally substituted by OH, C_1 - C_2 alkoxy, C_1 - C_2 fluoroalkoxy, CN, NH_2 , $NHCH_3$ or $N(CH_3)_2$;

each R^{29} and R^{30} is independently H, C_1 - C_4 alkyl or C_1 - C_4 fluoroalkyl, where each said
 5 C_1 - C_4 alkyl and C_1 - C_4 fluoroalkyl is optionally substituted by OH, C_1 - C_2 alkoxy, C_1 - C_2 fluoroalkoxy, CN, NH_2 , $NHCH_3$ or $N(CH_3)_2$;

m is 0, 1 or 2;


n is 0, 1, 2, 3 or 4;

p is 1, 2 or 3; and

10 q is 0, 1, 2 or 3;

wherein the sum of p and q is an integer from 1 to 4.

2. A compound of Formula (II):



or a pharmaceutically acceptable salt thereof, wherein:

15 R^1 is H, F, Cl, CN, C_1 - C_2 alkyl or C_1 - C_2 fluoroalkyl, where each said C_1 - C_2 alkyl and C_1 - C_2 fluoroalkyl is optionally substituted by R^{20} ;

U is NR^2 or CR^3 ;

V is N or CR^4 when U is NR^2 ; and

V is NR^5 when U is CR^3 ;

20 X is CR^6 or N;

Y is CR^7 or N;

Z is CR^8 or N;

R^2 and R^3 are H, C_1 - C_5 alkyl, C_1 - C_5 fluoroalkyl, C_3 - C_8 cycloalkyl or 3-6 membered heterocyclyl, where each said C_1 - C_5 alkyl and C_1 - C_5 fluoroalkyl is optionally substituted by R^{20}
 25 and each said C_3 - C_8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R^{21} ;

R^4 is H, C_1 - C_4 alkyl, C_1 - C_4 fluoroalkyl, C_1 - C_4 alkoxy or C_1 - C_4 fluoroalkoxy, where each said C_1 - C_4 alkyl, C_1 - C_4 fluoroalkyl, C_1 - C_4 alkoxy and C_1 - C_4 fluoroalkoxy is optionally substituted by R^{20} ;

R^5 is H, C_1 - C_4 alkyl or C_1 - C_4 fluoroalkyl, where each said C_1 - C_4 alkyl and C_1 - C_4 fluoroalkyl is optionally substituted by R^{20} ;

R^6 is H, F, Cl, CN, CH_3 , CH_2F , CHF_2 or CF_3 ;

R^7 and R^8 are independently H, F, Cl, CN, C_1 - C_2 alkyl, C_1 - C_2 fluoroalkyl, C_1 - C_2 alkoxy or C_1 - C_2 fluoroalkoxy, where each said C_1 - C_2 alkyl, C_1 - C_2 fluoroalkyl, C_1 - C_2 alkoxy and C_1 - C_2 fluoroalkoxy is optionally substituted by R^{20} ;

5 R^9 is H, OH, NH_2 , $NHCH_3$ or $N(CH_3)_2$;

each R^{10} is independently F, CN, C_1 - C_2 alkyl or C_1 - C_2 fluoroalkyl, where each said C_1 - C_2 alkyl and C_1 - C_2 fluoroalkyl is optionally substituted by R^{20} ;

Q is NR^{11} or O; or

10 Q is $CR^{12}R^{13}$, where R^{12} and R^{13} are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR^{11} or O as a ring member, which ring is optionally further substituted by R^{10} ;

R^{11} is H, C_1 - C_4 alkyl, C_1 - C_4 fluoroalkyl, SO_2R^{14} , $SO_2NR^{15}R^{16}$, COR^{17} , $COOR^{17}$ or $CONR^{18}R^{19}$;

R^{14} is C_1 - C_4 alkyl or C_1 - C_4 fluoroalkyl;

15 each R^{15} and R^{16} is independently H or CH_3 ;

R^{17} is C_1 - C_4 alkyl, C_1 - C_4 fluoroalkyl, where each said C_1 - C_4 alkyl and C_1 - C_4 fluoroalkyl is optionally substituted by R^{20} ;

each R^{18} and R^{19} is independently H, C_1 - C_4 alkyl or C_1 - C_4 fluoroalkyl, where each said C_1 - C_4 alkyl and C_1 - C_4 fluoroalkyl is optionally substituted by R^{20} ;

20 each R^{20} is independently OH, C_1 - C_2 alkoxy, C_1 - C_2 fluoroalkoxy, CN or $NR^{22}R^{23}$;

each R^{21} is independently F, OH, CN, $NR^{22}R^{23}$, C_1 - C_4 alkyl, C_1 - C_4 fluoroalkyl, C_1 - C_4 alkoxy or C_1 - C_4 fluoroalkoxy, where each said C_1 - C_4 alkyl, C_1 - C_4 fluoroalkyl, C_1 - C_4 alkoxy and C_1 - C_4 fluoroalkoxy is optionally further substituted by OH, NH_2 , $NHCH_3$ or $N(CH_3)_2$;

each R^{22} and R^{23} is independently H, C_1 - C_2 alkyl or C_1 - C_2 fluoroalkyl; or

25 R^{22} and R^{23} may be taken together with the nitrogen atom to which they are attached to form an azetidiny ring, which is optionally substituted by F or OH;


n is 0, 1, 2, 3 or 4;

p is 1, 2 or 3; and

q is 0, 1, 2 or 3;

30 wherein the sum of p and q is an integer from 1 to 4.

3. A compound of Formula (III):



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is H, F, Cl, CN, C₁-C₂ alkyl or C₁-C₂ fluoroalkyl, where each said C₁-C₂ alkyl and C₁-C₂ fluoroalkyl is optionally substituted by R²⁰;

5 U is NR² or CR³;

V is N or CR⁴ when U is NR²; and

V is NR⁵ when U is CR³;

X is CR⁶ or N;

Y is CR⁷ or N;

10 Z is CR⁸ or N;

R² and R³ are H, C₁-C₅ alkyl, C₁-C₅ fluoroalkyl, C₃-C₈ cycloalkyl or 3-6 membered heterocyclyl, where each said C₁-C₅ alkyl and C₁-C₅ fluoroalkyl is optionally substituted by R²⁰ and each said C₃-C₈ cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R²¹;

R⁴ is H, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy or C₁-C₄ fluoroalkoxy, where each said
15 C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy and C₁-C₄ fluoroalkoxy is optionally substituted by R²⁰;

R⁵ is H, C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R²⁰;

R⁶ is H, F, Cl, CN, CH₃, CH₂F, CHF₂ or CF₃;

R⁷ and R⁸ are independently H, F, Cl, CN, C₁-C₂ alkyl, C₁-C₂ fluoroalkyl, C₁-C₂ alkoxy or
20 C₁-C₂ fluoroalkoxy, where each said C₁-C₂ alkyl, C₁-C₂ fluoroalkyl, C₁-C₂ alkoxy and C₁-C₂ fluoroalkoxy is optionally substituted by R²⁰;

R⁹ is H, OH, NH₂, NHCH₃ or N(CH₃)₂;


each R¹⁰ is independently F, CN, C₁-C₂ alkyl or C₁-C₂ fluoroalkyl, where each said C₁-C₂ alkyl and C₁-C₂ fluoroalkyl is optionally substituted by R²⁰;

25 Q is NR¹¹ or O; or

Q is CR¹²R¹³, where R¹² and R¹³ are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR¹¹ or O as a ring member, which ring is optionally further substituted by R¹⁰;

R¹¹ is H, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, SO₂R¹⁴, SO₂NR¹⁵R¹⁶, COR¹⁷, COOR¹⁷ or
30 CONR¹⁸R¹⁹;

- R¹⁴ is C₁-C₄ alkyl or C₁-C₄ fluoroalkyl;
 each R¹⁵ and R¹⁶ is independently H or CH₃;
 R¹⁷ is C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R²⁰;
- 5 each R¹⁸ and R¹⁹ is independently H, C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R²⁰;
 each R²⁰ is independently OH, C₁-C₂ alkoxy, C₁-C₂ fluoroalkoxy, CN or NR²²R²³;
 each R²¹ is independently F, OH, CN, NR²²R²³, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy or C₁-C₄ fluoroalkoxy, where each said C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy and C₁-C₄
- 10 fluoroalkoxy is optionally further substituted by OH, NH₂, NHCH₃ or N(CH₃)₂;
 each R²² and R²³ is independently H, C₁-C₂ alkyl or C₁-C₂ fluoroalkyl; or
 R²² and R²³ may be taken together with the nitrogen atom to which they are attached to form an azetidiny ring, which is optionally substituted by F or OH;
- n is 0, 1, 2, 3 or 4;
- 15 p is 1, 2 or 3; and
 q is 0, 1, 2 or 3;
 wherein the sum of p and q is an integer from 1 to 4.
4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein X is CR⁶, Y is CR⁷ and Z is CR⁸.
- 20 5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein U is NR² and V is CR⁴.
6. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein U is CR³ and V is NR⁵.
7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof,
- 25 wherein Q is O.
8. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Q is NR¹¹.
9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R⁹ is OH.
- 30 10. A compound of Formula (IX):



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is H, F, Cl, CN, C₁-C₂ alkyl or C₁-C₂ fluoroalkyl, where each said C₁-C₂ alkyl and C₁-C₂ fluoroalkyl is optionally substituted by R²⁰;

- 5 R² is H, C₁-C₅ alkyl, C₁-C₅ fluoroalkyl, C₃-C₈ cycloalkyl or 3-6 membered heterocyclyl, where each said C₁-C₅ alkyl and C₁-C₅ fluoroalkyl is optionally substituted by R²⁰ and each said C₃-C₈ cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R²¹;

- R⁴ is H, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy or C₁-C₄ fluoroalkoxy, where each said C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy and C₁-C₄ fluoroalkoxy is optionally substituted
10 by R²⁰;

R⁶ is H, F, Cl, CN, CH₃, CH₂F, CHF₂ or CF₃;

R⁷ and R⁸ are independently H, F, Cl, CN, C₁-C₂ alkyl, C₁-C₂ fluoroalkyl, C₁-C₂ alkoxy or C₁-C₂ fluoroalkoxy, where each said C₁-C₂ alkyl, C₁-C₂ fluoroalkyl, C₁-C₂ alkoxy and C₁-C₂ fluoroalkoxy is optionally substituted by R²⁰;

- 15 R⁹ is H, OH, NH₂, NHCH₃ or N(CH₃)₂;

each R¹⁰ is independently F, CN, C₁-C₂ alkyl or C₁-C₂ fluoroalkyl, where each said C₁-C₂ alkyl and C₁-C₂ fluoroalkyl is optionally substituted by R²⁰;

R¹¹ is H, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, SO₂R¹⁴, SO₂NR¹⁵R¹⁶, COR¹⁷, COOR¹⁷ or CONR¹⁸R¹⁹;

- 20 R¹⁴ is C₁-C₄ alkyl or C₁-C₄ fluoroalkyl;

each R¹⁵ and R¹⁶ is independently H or CH₃;

R¹⁷ is C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R²⁰;

- each R¹⁸ and R¹⁹ is independently H, C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said
25 C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R²⁰;

each R²⁰ is independently OH, C₁-C₂ alkoxy, C₁-C₂ fluoroalkoxy, CN or NR²²R²³;

each R²¹ is independently F, OH, CN, NR²²R²³, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy or C₁-C₄ fluoroalkoxy, where each said C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy and C₁-C₄ fluoroalkoxy is optionally further substituted by OH, NH₂, NHCH₃ or N(CH₃)₂;


each R^{22} and R^{23} is independently H, C_1 - C_2 alkyl or C_1 - C_2 fluoroalkyl; or

R^{22} and R^{23} may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH; and
n is 0, 1, 2, 3 or 4.

5

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein R^{11} is SO_2R^{14} and R^{14} is C_1 - C_4 alkyl.

12. A compound of Formula (XI):



10

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is H, F, Cl, CN, C_1 - C_2 alkyl or C_1 - C_2 fluoroalkyl, where each said C_1 - C_2 alkyl and C_1 - C_2 fluoroalkyl is optionally substituted by R^{20} ;

R^2 is H, C_1 - C_5 alkyl, C_1 - C_5 fluoroalkyl, C_3 - C_8 cycloalkyl or 3-6 membered heterocyclyl, where each said C_1 - C_5 alkyl and C_1 - C_5 fluoroalkyl is optionally substituted by R^{20} and each said
15 C_3 - C_8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R^{21} ;

R^4 is H, C_1 - C_4 alkyl, C_1 - C_4 fluoroalkyl, C_1 - C_4 alkoxy or C_1 - C_4 fluoroalkoxy, where each said C_1 - C_4 alkyl, C_1 - C_4 fluoroalkyl, C_1 - C_4 alkoxy and C_1 - C_4 fluoroalkoxy is optionally substituted by R^{20} ;
or

R^2 can be taken together with R^4 to form a 5-7 membered heterocyclic ring, optionally
20 containing an additional heteroatom selected from NR^{24} , O and $S(O)_m$ as a ring member, which ring is optionally substituted by R^{21} ;

R^6 is H, F, Cl, CN, CH_3 , CH_2F , CHF_2 or CF_3 ;

R^7 and R^8 are independently H, F, Cl, CN, C_1 - C_2 alkyl, C_1 - C_2 fluoroalkyl, C_1 - C_2 alkoxy or
25 C_1 - C_2 fluoroalkoxy, where each said C_1 - C_2 alkyl, C_1 - C_2 fluoroalkyl, C_1 - C_2 alkoxy and C_1 - C_2 fluoroalkoxy is optionally substituted by R^{20} ;

R^9 is H, OH, NH_2 , $NHCH_3$ or $N(CH_3)_2$;

each R^{10} is independently F, CN, C_1 - C_2 alkyl or C_1 - C_2 fluoroalkyl, where each said C_1 - C_2 alkyl and C_1 - C_2 fluoroalkyl is optionally substituted by R^{20} ;

each R^{20} is independently OH, C_1 - C_2 alkoxy, C_1 - C_2 fluoroalkoxy, CN or $NR^{22}R^{23}$;

each R²¹ is independently F, OH, CN, NR²²R²³, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy or C₁-C₄ fluoroalkoxy, where each said C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy and C₁-C₄ fluoroalkoxy is optionally further substituted by OH, NH₂, NHCH₃ or N(CH₃)₂;

each R²² and R²³ is independently H, C₁-C₂ alkyl or C₁-C₂ fluoroalkyl; or

5 R²² and R²³ may be taken together with the nitrogen atom to which they are attached to form an azetidiny ring, which is optionally substituted by F or OH;

R²⁴ is H, C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, SO₂R²⁵, SO₂NR²⁶R²⁷, COR²⁸, COOR²⁸ or CONR²⁹R³⁰;

R²⁵ is C₁-C₄ alkyl or C₁-C₄ fluoroalkyl;

10 each R²⁶ and R²⁷ is independently H or CH₃;

R²⁸ is C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by OH, C₁-C₂ alkoxy, C₁-C₂ fluoroalkoxy, CN, NH₂, NHCH₃ or N(CH₃)₂;

each R²⁹ and R³⁰ is independently H, C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by OH, C₁-C₂ alkoxy, C₁-C₂ fluoroalkoxy, 15 CN, NH₂, NHCH₃ or N(CH₃)₂;

m is 0, 1 or 2; and

n is 0, 1, 2, 3 or 4.

13. The compound of claim 10, 11 or 12, or a pharmaceutically acceptable salt thereof, 20 wherein R¹ is Cl.

14. The compound of any one of claims 10 to 13, or a pharmaceutically acceptable salt thereof, wherein R² is C₁-C₅ alkyl, where said C₁-C₅ alkyl is optionally substituted by R²⁰.

15. The compound of any one of claims 10 to 14, or a pharmaceutically acceptable salt thereof, wherein R⁴ is C₁-C₄ alkyl, where said C₁-C₄ alkyl is optionally substituted by R²⁰.

25 16. The compound of any one of claims 10 to 15, or a pharmaceutically acceptable salt thereof, wherein R⁶ is F, R⁷ is H, and R⁸ is H.

17. The compound of any one of claims 10 to 16, or a pharmaceutically acceptable salt thereof, wherein R⁹ is OH.

30 18. (3*R*,4*R*)-4-[(5-chloro-4-{4-fluoro-2-[(1*R*)-1-hydroxyethyl]-1-(propan-2-yl)-1*H*-benzimidazol-6-yl}pyrimidin-2-yl)amino]-1-(methanesulfonyl)piperidin-3-ol, or a pharmaceutically acceptable salt thereof.

19. 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1*H*-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-*threo*-pentitol, or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising the compound of any one of claims 1 to 19, or
5 a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

21. A method for the treatment of cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof.

10 22. A compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a subject in need thereof.

23. A compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, wherein said treatment comprises the administration of a second pharmaceutically active agent.

15